Robert Davis, Merck CEO
July 7, 2022 06:59 AM EDT
Deals
Bioregnum

Fresh re­port of 'ad­vanced' $40B+ Seagen buy­out talks spurs more buzz about FTC show­down

Mer­ck CEO Rob Davis ap­pears com­mit­ted to push­ing through with a $40 bil­lion (or so) buy­out deal with Seagen, dri­ven by its need to be …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Cal­i­co, De­nal­i's ALS drugs miss pri­ma­ry ob­jec­tives in bas­ket study

Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy

Met­sera’s long-act­ing GLP-1 looks com­pet­i­tive in Phase 2 obe­si­ty study

Ex­clu­sive: Aven­zo picks up an­oth­er ADC, this time with mul­ti-part­nered Du­al­i­ty­Bio

Ken Song's Can­did li­cens­es a T cell en­gager from WuXi Bio

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

A service from the Financial Times